MedTrace Logo

Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer

NCT00888511 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-11-27

Study results available
· View outcomes & findings →

Summary

The trial is a phase II study of daily Tarceva combined with definitive radiotherapy in inoperable locally advanced non small cell lung cancer (stage IIB-IIIB). The objective of the phase II trial is to examine Tarceva concomitant with curatively intended irradiation 66 Gy (2 Gy x 33 F, 5 F per week).

Conditions

Interventions

DRUG

Tarceva

Tarceva 150 mg/day

RADIATION

Radiotherapy

66 Gy/33 F/5 F per week for 5 weeks

Sponsors & Collaborators

  • Odense University Hospital

    collaborator OTHER

  • Copenhagen University Hospital at Herlev

    collaborator OTHER

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Aalborg University Hospital

    collaborator OTHER

  • Aarhus University Hospital

    collaborator OTHER

  • Naestved Hospital

    collaborator OTHER

  • Olfred Hansen

    lead OTHER

Principal Investigators

  • Olfred Hansen, MD · Odense University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00888511 on ClinicalTrials.gov